Journal of Emergency Practice and Trauma

Aspirin Resistance in Coronary Artery Disease: Prevalence and Clinical Implications

Document Type : Original Article

Authors

mohammadreza dolikhani 1
Ghazaleh Shakibamaram 1
mohsen karami 2
arezoo barati 2
Anita Sabzghabaei 3

1 Bone Joint and Related Tissues Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 Emergency Medicine Department, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

https://doi.org/doi:10.34172/jept.1777
Abstract
Introduction: Coronary artery disease (CAD) remains a major cause of morbidity and mortality worldwide. Aspirin is a cornerstone in CAD management due to its antiplatelet effects; however, aspirin resistance can lead to suboptimal outcomes. In Iran, limited data exist regarding the prevalence of aspirin resistance among patients presenting with chest pain. This study aimed to determine the prevalence of aspirin resistance and its clinical implications in a cohort of Iranian patients with CAD.
Methods: This prospective cross-sectional study was conducted in 2021 at the Emergency Department of Imam Hossein Hospital, Tehran, Iran. A total of 155 patients aged ≥ 18 years on daily aspirin therapy ( ≥ 75 mg for ≥ 7 days) were recruited using convenience sampling. Bleeding time was measured by the standard SimPlate method (resistance defined as BT < 5 minutes). Normality of variables was tested with the Shapiro–Wilk test; between-group comparisons were performed using the t-test for continuous variables and the χ² test for categorical variables. Statistical significance was defined as P < 0.05.
Results: Among 155 participants (mean age 57.49 ± 13.13 years; 59.4% male), 133 (85.8%) exhibited aspirin resistance. Resistant patients were significantly older than sensitive ones (59.64 ± 12.47 vs. 44.50 ± 9.05 years; P < 0.001). No gender difference was observed (P = 0.363). Compared with aspirin-sensitive patients, resistant patients had higher rates of hypertension (42.1% vs. 18.2%; P = 0.033), diabetes mellitus (42.9% vs. 9.1%; P = 0.003), and hyperlipidemia (32.3% vs. 0%; P = 0.002). Finally, hospitalization was more frequent in resistant patients (81.2% vs. 22.7%; P < 0.001).
Conclusion: These findings indicate that aspirin resistance is prevalent among Iranian CAD patients and is strongly associated with older age and increased cardiovascular risk factors, underscoring its clinical significance. Routine screening for aspirin resistance should be integrated into CAD management protocols, enabling personalized antiplatelet strategies and ultimately improving patient outcomes.

Keywords

Coronary artery disease
Aspirin resistance
BT
Chest pain
Cardiovascular risk factors
Subjects
1. Pintea Bentea G, Berdaoui B, Morissens M, van de Borne P, Castro Rodriguez J. Pathophysiology, diagnosis, and management of coronary artery disease in the setting of atrial fibrillation. J Am Heart Assoc 2024;13(23):e037552. doi:10.1161/jaha.124.037552
2. Mack M, Gopal A. Epidemiology, traditional and novel risk factors in coronary artery disease. Heart Fail Clin 2016;12(1):1-10. doi:10.1016/j.hfc.2015.08.002
3. Dai H, Much AA, Maor E, Asher E, Younis A, Xu Y, et al. Global, regional, and national burden of ischaemic heart disease and its attributable risk factors, 1990-2017: results
from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes 2022;8(1):50-60. doi:10.1093/ehjqcco/qcaa076
4. Khalid N, Haider S, Abdullah M, Asghar S, Laghari MA, Rajeswaran Y. Trends and disparities in coronary artery disease prevalence among US adults from 2019 to 2022.
Curr Probl Cardiol 2024;49(8):102645. doi:10.1016/j.cpcardiol.2024.102645
5. Gerber Y, Weston SA, Jiang R, Roger VL. The changing epidemiology of myocardial infarction in Olmsted county, Minnesota, 1995-2012. Am J Med 2015;128(2):144-51.
doi:10.1016/j.amjmed.2014.09.012
6. Loscalzo J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison’s Principles of Internal Medicine. 21st ed. McGraw Hill; 2022.
7. Gelbenegger G, Postula M, Pecen L, Halvorsen S, Lesiak M, Schoergenhofer C, et al. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular
focus on subgroups. BMC Med 2019;17(1):198. doi:10.1186/s12916-019-1428-0
8. Gu Q, Dillon CF, Eberhardt MS, Wright JD, Burt VL. Preventive aspirin and other antiplatelet medication use among US adults aged ≥ 40 years: data from the National Health and
Nutrition Examination Survey, 2011-2012. Public Health Rep 2015;130(6):643-54. doi:10.1177/003335491513000614
9. Van’t Hof JR, Duval S, Oldenburg NC, Misialek JR, Eder MM, Jones C, et al. Low-dose aspirin for primary prevention of cardiovascular disease: trends in use patterns among
African American adults in Minnesota, 2015-2019. Prev Med 2021;148:106589. doi:10.1016/j.ypmed.2021.106589
10. Protty MB, Tyrrell VJ, Hajeyah AA, Morgan B, Costa D, Li Y, et al. Aspirin modulates generation of procoagulant phospholipids in cardiovascular disease, by regulating
LPCAT3. J Lipid Res 2025;66(1):100727. doi:10.1016/j.jlr.2024.100727
11. Ahn TG, Hwang JY. Preeclampsia and aspirin. Obstet Gynecol Sci 2023;66(3):120-32. doi:10.5468/ogs.22261
12. Giménez-Bastida JA, Boeglin WE, Boutaud O, Malkowski MG, Schneider C. Residual cyclooxygenase activity of aspirin-acetylated COX-2 forms 15 R-prostaglandins that
inhibit platelet aggregation. FASEB J 2019;33(1):1033-41.doi:10.1096/fj.201801018R
13. Khan H, Kanny O, Syed MH, Qadura M. Aspirin resistance in vascular disease: a review highlighting the critical need for improved point-of-care testing and personalized therapy. Int J
Mol Sci 2022;23(19):11317. doi:10.3390/ijms231911317
14. Du G, Lin Q, Wang J. A brief review on the mechanisms of aspirin resistance. Int J Cardiol 2016;220:21-6. doi:10.1016/j.ijcard.2016.06.104
15. Chen HY, Chou P. PFA-100-measured aspirin resistance is the predominant risk factor for hospitalized cardiovascular events in aspirin-treated patients: a 5-year cohort study. J Clin Pharm
Ther 2018;43(2):249-55. doi:10.1111/jcpt.12643
16. Ebrahimi P, Farhadi Z, Behzadifar M, Shabaninejad H, Abolghasem Gorji H, Taheri Mirghaed M, et al. Prevalence rate of laboratory defined aspirin resistance in cardiovascular
disease patients: a systematic review and meta-analysis. Caspian J Intern Med 2020;11(2):124-34. doi:10.22088/cjim.11.2.124
17. Han YL. Aspirin resistance in coronary heart disease: current understandings and strategies. J Transl Int Med 2016;4(1):7-10. doi:10.1515/jtim-2016-0002
18. Arockiam S, Staniforth B, Kepreotis S, Maznyczka A, Bulluck H. A contemporary review of antiplatelet therapies in current clinical practice. Int J Mol Sci 2023;24(13):11132.
doi:10.3390/ijms241311132
19. Sadeghi M, Emami A, Ziyaei N, Yaran M, Golabchi A, Sadeghi A. Aspirin resistance and ischemic heart disease on Iranian experience. Adv Biomed Res 2012;1:33. doi:10.4103/2277-9175.99345
20. Sundram E, Kharaharilal P, Ilavarasu S, Renukadevi, Nalini E, Karunamoorthy V. Evaluative comparison of systemic aspirin therapy effects on gingival bleeding in post nonsurgical
periodontal therapy individuals. J Pharm Bioallied Sci 2012;4(Suppl 2):S221-5. doi:10.4103/0975-7406.100210
21. Russeau AP, Vall H, Manna B. Bleeding time. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2023.
22. Yassin AS, Abubakar H, Mishra T, Subahi A, Hartman M, Ahmed A, et al. Aspirin resistance: cardiovascular risk game changer. Am J Ther 2019;26(5):593-9. doi:10.1097/mjt.0000000000000780
23. Cai G, Zhou W, Lu Y, Chen P, Lu Z, Fu Y. Aspirin resistance and other aspirin-related concerns. Neurol Sci 2016;37(2):181-9. doi:10.1007/s10072-015-2412-x
24. Ziaie N, Sadeghi M, Akhlaghi A, Pirhaji O, Yaran M, Pourmoghadas M. Aspirin resistance status as determined by urinary thromboxane B2 (TXB2) level in patients with ischemic
heart disease and its relationship with severity of coronary artery disease. J Isfahan Med Sch 2010;28(116):1008-15.
25. Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008;100(3):379-90. doi:10.1160/TH08-01-0056
26. Li CX, Sun LC, Wang YQ, Liu TT, Cai JR, Liu H, et al. The associations of candidate gene polymorphisms with aspirin resistance in patients with ischemic disease: a meta-analysis.
Hum Genomics 2024;18(1):135. doi:10.1186/s40246-024-00699-1
Journal of Emergency Practice and Trauma
Volume 11, Issue 1
January 2025
Pages 27-32

  • Receive Date 18 September 2025
  • Revise Date 02 October 2025
  • Accept Date 13 October 2025

Home

Editor-in-Chief: Shahrad Tajoddini, MD

Guide for Authors

Submit Manuscript

Reviewers

Contact Us

Editorial board